Characteristics of Patients With Philadelphia Negative Myeloproliferative Neoplasms at Assiut University Hospital
NCT05401864 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2022-06-08
Summary
Classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are a family of clonal chronic hematologic malignancies that include. polycythemia vera (PV), essential thrombocythemia (ET), and primary. Myelofibrosis (MF) . The classic MPNs historically have predominantly been diagnosed in older adults, with a median age at diagnosis of 60-72 years . Adults less than 40 years of age make up a largely underrepresented and therefore less studied subset of patients constituting 2.2-6.6% of yearly MPN cases in population- based study. These estimates are lower than incidence rate among patients between 40 and 49 years of age (9.1-10%), and have remained largely unchanged over the past four decades . However, with increasing trends in MPN incidence consequent to increased diagnostic recognition, better pathobiologic understanding, and more frequent JAK2/CALR/MPL mutational testing and newly revised WHO diagnostic criteria, it is conceivable that MPNs may be diagnosed at a higher frequency, in the younger patients, over time.
Conditions
- Philadelphia Negative Myeloproliferative Neoplasms
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-06-30
- Primary Completion
- 2023-12-31
- Completion
- 2024-06-30
More Related Trials
-
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
NCT03065400 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Collection of Biological Data of Prognostic Relevance in Patients With B-Cell Chronic Lymphocytic Leukemia
NCT00917540 ·Status: UNKNOWN
-
A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL
NCT05931757 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT00982488 ·Status: COMPLETED ·Phase: PHASE2
-
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients
NCT05112653 ·Status: UNKNOWN
-
Momelotinib Effectiveness in Myelofibrosis
NCT07249606 ·Status: NOT_YET_RECRUITING
-
Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
NCT03318770 ·Status: UNKNOWN
-
Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
NCT07250087 ·Status: RECRUITING ·Phase: PHASE1
-
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
NCT02143414 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults
NCT02611492 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
NCT04722848 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
NCT01670084 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan
NCT00337454 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ruxolitinib in Patients With Myelofibrosis
NCT05762874 ·Status: UNKNOWN
-
Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL
NCT05559450 ·Status: RECRUITING ·Phase: PHASE2
-
Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.
NCT02546674 ·Status: COMPLETED ·Phase: PHASE4
-
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
NCT05071482 ·Status: TERMINATED ·Phase: PHASE4
-
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
NCT02362035 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis
NCT05447260 ·Status: UNKNOWN ·Phase: PHASE4
-
Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities
NCT00546897 ·Status: COMPLETED ·Phase: PHASE2
-
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
NCT01433445 ·Status: COMPLETED ·Phase: PHASE1
-
Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study
NCT00978731 ·Status: COMPLETED ·Phase: PHASE1
-
An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®
NCT02455024 ·Status: TERMINATED